ライフサイエンスコーパス: muscarinic agonist

1 nd is classified as either a full or partial muscarinic agonist.

2 y multiple calcium responses to carbachol, a muscarinic agonist.

3 24Z is functionally an m1-selective muscarinic agonist.

4 d 63% by 10 microM oxotremorine M (Oxo-M), a muscarinic agonist.

5 h is known to be an M(1)- and M(4)-selective muscarinic agonist.

6 rol M-current over-recovery after washout of muscarinic agonist.

7 A-090, an NMDA antagonist; and WAY-132983, a muscarinic agonist.

8 tion--when worms are exposed to arecoline, a muscarinic agonist.

9 ator circuit within CA1 that is activated by muscarinic agonists.

10 underlie the cognition-enhancing effects of muscarinic agonists.

11 ut can fire spontaneously when stimulated by muscarinic agonists.

12 upon either ACh release or its modulation by muscarinic agonists.

13 larizing current stimulus in the presence of muscarinic agonists.

14 minal kinase activation by neuropeptides and muscarinic agonists.

15 thyl-D-aspartate (NMDA)-receptor currents by muscarinic agonists.

16 one, and asthmatics exhibit increased AHR to muscarinic agonists.

17 eral responses associated with non-selective muscarinic agonists.

18 nt mutant receptors with full versus inverse muscarinic agonists.

19 in magnitude and somewhat less than that by muscarinic agonists.

20 -cells, and these processes are amplified by muscarinic agonists.

21 ation by acetylcholine, carbachol, and other muscarinic agonists.

22 2+) influx and release elicited by different muscarinic agonists.

23 1,4-dioxane scaffold of the potent M(2)/M(3) muscarinic agonist 1 with bulkier groups.

24 iazoles to provide a new series of potent m1 muscarinic agonists 17 and 18.

25 The acetyl group of the muscarinic agonist aceclidine 4 was replaced by various

26 The muscarinic agonist acetylcholine (10 micrograms/kg IV) i

27 overcome by increasing concentrations of the muscarinic agonist acetylcholine but was progressively l

28 The muscarinic agonist ACh inhibited the Ca(2+) current stim

29 The data suggest that muscarinic agonists act as functional dopamine antagonis

30 timulation of these mAChRs with carbachol, a muscarinic agonist, activated extracellular-regulated ki

31 Nicotine, but not muscarinic agonists, activates postsynaptic receptors an

32 tetrahydropyrimidine derivatives exhibiting muscarinic agonist activity in rat brain.

33 and tested for receptor binding affinity and muscarinic agonist activity.

34 Systemic administration of 3 M1-selective muscarinic agonists, AF102B, AF150S and AF267B, decrease

35 the therapeutic efficacy of the selective M1 muscarinic agonist AF267B in the 3xTg-AD model of Alzhei

36 Intraseptal muscarinic agonists also alleviate the amnesic syndrome

37 Remarkably, muscarinic agonists also cause long-term (>30 min) suppr

38 Specific nicotinic and muscarinic agonists also elevated [Ca2+]i in a dose-depe

39 However, muscarinic agonists also elicit a long-term (2 hr) suppr

40 Muscarinic agonists also induce and atropine potently in

41 bradykinin, but reduced I(M) suppression by muscarinic agonist and angiotensin II.

42 Interestingly, incubation with classical muscarinic agonists and antagonists or allosteric ligand

43 ng kinetics and pharmacological responses to muscarinic agonists and GTPgammaS.

44 basis for the opposing biological effects of muscarinic agonists and inverse agonists.

45 neuroblastoma and sympathetic neurons, both muscarinic agonists and nitric oxide (NO) rapidly elevat

46 iments on neuroblastoma cells show that both muscarinic agonists and NO rapidly elevate cGMP.

47 Oxotremorine (a muscarinic agonist) and (-)butylthio[2.2.2] (a mixed mus

48 2+) and 2.5 microm oxotremorine M (oxo-M), a muscarinic agonist, and fully blocked by zero Ca(2+), 10

49 receptors yielded large [Ca(2+)](i) rises by muscarinic agonist, and transfection of wild-type IRBIT

50 strongly depolarized by bath application of muscarinic agonists, and uniformly lacked a similar musc

51 ic agonist) and (-)butylthio[2.2.2] (a mixed muscarinic agonist/antagonist) dose-dependently inhibite

52 ing of the specific mechanisms through which muscarinic agonists are likely to modulate neuronal exci

53 injections of cholinomimetic drugs, either a muscarinic agonist (arecoline, pilocarpine or oxotremori

54 he development of receptor subtype-selective muscarinic agonists as novel analgesic drugs.

55 systemic pretreatment with the pro-motility muscarinic agonist bethanechol, but were abolished by sy

56 lacking RGS4 in pancreatic beta-cells with a muscarinic agonist (bethanechol) led to significantly in

57 gastric motility in rats pretreated with the muscarinic agonist, bethanecol (P < 0.05).

58 Disulfide cross-linking studies showed that muscarinic agonists, but not antagonists, promoted the f

59 f muscarinic receptors as it was mimicked by muscarinic agonists, but not by nicotine, and was blocke

60 In the presence of muscarinic agonists, Ca2+i responses consisted of an ini

61 vitro evidence that a brief application of a muscarinic agonist can transiently synchronize islets.

62 native or recombinant channels inhibited by muscarinic agonists can be activated by PIP(2).

63 reated with ethanol, and stimulated with the muscarinic agonist carbachol (1 muM).

64 -40 mV), and were inhibited by bath-applied muscarinic agonist carbachol (10 microm).

65 The mixed muscarinic agonist carbachol (CAR) hyperpolarized all ty

66 Acinar cell responses to the muscarinic agonist carbachol (CCh) and the bile acid tau

67 The effects of the cholinergic muscarinic agonist carbachol (CCh) on the basal L-type c

68 The muscarinic agonist carbachol also prevented beta-AR-stim

69 a contractile phenotype that responds to the muscarinic agonist carbachol and is not immediately reve

70 sis when the cells are preincubated with the muscarinic agonist carbachol for > or = 5 min and forsko

71 -methyl-D-aspartate receptor currents by the muscarinic agonist carbachol in hippocampal pyramidal ce

72 The muscarinic agonist carbachol increased IK+Ach activity i

73 dye fluo-4 AM were captured; exposure to the muscarinic agonist carbachol increased the fluorescence

74 The muscarinic agonist carbachol induced pronounced transien

75 ary cells expressing m3 mAChRs, doses of the muscarinic agonist carbachol ranging from 100 nM to 1 mM

76 Application of the muscarinic agonist carbachol reduced peak Na+ current an

77 In this system, the muscarinic agonist carbachol stimulated steady-state PLC

78 A half-maximal effect of the muscarinic agonist carbachol was observed at approximate

79 lls, in acini stimulated to secrete with the muscarinic agonist carbachol, and in acini shrunken by h

80 P by approximately 90% in the absence of the muscarinic agonist carbachol, indicating that these tyrp

81 al rat ventricular myocytes treated with the muscarinic agonist carbachol.

82 to the negative chronotropic effects of the muscarinic agonist carbachol.

83 isolated smooth muscle cells induced by the muscarinic agonist carbachol.

84 phorylation and contractile responses to the muscarinic agonist carbachol.

85 ccurred in eggs in low pH in response to the muscarinic agonist carbachol.

86 imulation of beta cells with glucose and the muscarinic agonist carbachol.

87 tion upon pharmacological treatment with the muscarinic agonist carbachol.

88 ractility in the presence and absence of the muscarinic agonist carbachol.

89 transients were generated on exposure to the muscarinic agonist carbachol.

90 esponse curves have been constructed for the muscarinic agonists carbachol, acetylcholine, and piloca

91 In BHK cells expressing M1 receptors, a muscarinic agonist (carbachol) causes a 40% decrease of

92 We have shown previously that the muscarinic agonist, carbachol (CCh), transactivates the

93 cross-linking experiments revealed that the muscarinic agonist, carbachol, promoted the formation of

94 wing treatment with PMA or the acetylcholine muscarinic agonist, carbachol.

95 her in the absence or in the presence of the muscarinic agonist, carbachol.

96 th in the absence and in the presence of the muscarinic agonist, carbachol.

97 s abolished) the attenuation of ICa-L by the muscarinic agonist carbamylcholine (CCh).

98 ICa-L had been previously attenuated by the muscarinic agonist carbamylcholine (CCh, 1 mumol/L), SIN

99 rasympathetic inhibition of beat rate by the muscarinic agonist, carbamylcholine, by 5-fold and decre

100 Muscarinic agonists cause a rapid increase in presynapti

101 Activation of this pathway with muscarinic agonists caused UNC-13 to accumulate in punct

102 that treatment of chick embryos in ovo with muscarinic agonist causes decreases in mRNA levels encod

103 In contrast, two novel muscarinic agonists chemically derived from epibatidine,

104 The M1 muscarinic agonist CI-1017 was administered intravenousl

105 by reduced insulin secretion in response to muscarinic agonists, combined with increased peripheral

106 Selective muscarinic agonists could be useful in the treatment of

107 studies were conducted to determine whether muscarinic agonists could change outflow facility in per

108 Muscarinic agonists decreased AC activity, LVEF, and hea

109 duced (or stabilized) by full versus inverse muscarinic agonists differ from each other at the molecu

110 Centrally active muscarinic agonists display pronounced analgesic effects

111 rons in rat brain slices, we have found that muscarinic agonists do not excite septohippocampal choli

112 Muscarinic agonists do not induce dauer recovery of eith

113 ground conductances strongly attenuated most muscarinic agonist effects, with the notable exception t

114 unds with high muscarinic affinity and/or m1 muscarinic agonist efficacy were also obtained when the

115 Muscarinic agonists elevate cGMP by triggering Ca2+ mobi

116 Muscarinic agonists evoked reflexes that were associated

117 edly without decrement, whereas responses to muscarinic agonists exhibit a profound and prolonged des

118 However, infusion of either nicotinic or muscarinic agonists failed to improve choice accuracy.

119 rt to design and synthesize highly selective muscarinic agonists for different muscarinic receptor su

120 We also demonstrated that full and inverse muscarinic agonists had distinct effects on the efficien

121 , two other (nor)tropanes, and the classical muscarinic agonists had higher affinity versus agonist b

122 Many muscarinic agonists have been developed, yet most exhibi

123 Previously developed muscarinic agonists have provided clinical data in suppo

124 current potassium channel activity evoked by muscarinic agonists in sympathetic ganglion neurons is c

125 ellular mechanisms underlying the effects of muscarinic agonists in the MSDB involve an excitation of

126 X-sensitive IK(Ca) could be activated by the muscarinic agonists in the presence or absence of extern

127 produced by CI-1017, an M(1)/M(4) selective muscarinic agonist, in the mesolimbic region and striatu

128 Muscarinic agonists increase outflow facility in human e

129 Muscarinic agonists increased the input resistance of ne

130 s transiently expressing the m2 mAChR with a muscarinic agonist induced an approximately 4- or 8-fold

131 Although muscarinic agonists induced robust activation of MAPK in

132 treatment of caged bees with pilocarpine, a muscarinic agonist, induced an increase in the volume of

133 AA, and inhibiting iPLA(2)beta prevents the muscarinic agonist-induced accelerated Kv2.1 inactivatio

134 Strikingly, muscarinic agonist-induced antinociception was totally a

135 t M(5) receptors play a role in facilitating muscarinic agonist-induced dopamine release in the stria

136 Finally, muscarinic agonist-induced InsP3R ubiquitination was see

137 Previous work has suggested that muscarinic agonist-induced jaw movements in rats were re

138 Finally, muscarinic agonist-induced smooth muscle contraction als

139 Carbachol, a muscarinic agonist, induces prolonged activation of ERKI

140 xamined the roles of M(1) and M(3) mAChRs in muscarinic agonist-mediated stimulation of salivary secr

141 HEK293) cells with low concentrations of the muscarinic agonist methacholine results in the activatio

142 Airway resistance responses (Raw) to the muscarinic agonist methacholine were measured by using t

143 Muscarinic agonists might be useful in the treatment of

144 In neurons, muscarinic agonists mobilize an AKAP79-anchored pool of

145 Muscarinic agonists modulate N- and L-type Ca(2+) channe

146 The muscarinic agonist of chloride secretion, carbachol (CCh

147 In vitro stimulation with a muscarinic agonist of submandibular gland cells isolated

148 ibility that there may be a direct effect of muscarinic agonists on outflow facility.

149 effects of bradykinin and oxotremorine-M (a muscarinic agonist) on membrane PIP(2) in sympathetic ne

150 ved whether the channels were activated by a muscarinic agonist or by OAG.

151 administered without prior administration of muscarinic agonist or cholinesterase inhibitor) produced

152 cotine but contracted when stimulated with a muscarinic agonist or electric field stimulation.

153 se but potentiated the stimulation by either muscarinic agonists or 2-methyl-thio-ADP.

154 either in the absence or in the presence of muscarinic agonists or antagonists.

155 timulating mouse-eye pupil constriction than muscarinic agonists oxotremorin-M (Oxo-M) or carbachol (

156 om wild-type mice, the non-subtype-selective muscarinic agonist oxotremorine led to concentration-dep

157 The muscarinic agonist oxotremorine methiodide (oxo-M) stimu

158 isolate the slow pathway, we found that the muscarinic agonist oxotremorine methiodide not only inhi

159 The muscarinic agonist oxotremorine methiodide produced a do

160 The muscarinic agonist oxotremorine restores the plateau pot

161 The nonselective muscarinic agonist oxotremorine showed reduced analgesic

162 bellar slices, we have demonstrated that the muscarinic agonist oxotremorine-m (oxo-m) blocks the ind

163 c KCNQ2/KCNQ3 currents were modulated by the muscarinic agonist oxotremorine-M (oxo-M) in a manner ha

164 n, following treatment with the nonselective muscarinic agonist oxotremorine-M, M2, and M4 receptors

165 itivity upon challenge with the nonselective muscarinic agonist oxotremorine.

166 The standard muscarinic agonists oxotremorine and pilocarpine were bo

167 ine were 60-75% of the magnitude of the full muscarinic agonists oxotremorine-M and cis-dioxolane.

168 The nonsubtype-selective muscarinic agonist, oxotremorine (0.1-10 microm), inhibi

169 The M(1) muscarinic agonist pilocarpine blocked phosphorylation o

170 in electroencephalograms, SE induced by the muscarinic agonist pilocarpine in mice is preceded by a

171 Systemic administration of the nonselective muscarinic agonist pilocarpine induces pronounced striat

172 Application of the muscarinic agonist pilocarpine mimicked the effect of IP

173 n applied at a low dose (1 mg/kg, s.c.), the muscarinic agonist pilocarpine showed significantly redu

174 The ability of the partial muscarinic agonist pilocarpine to increase in vivo phosp

175 receptor function tested 24 h later with the muscarinic agonist pilocarpine.

176 s produced by systemic administration of the muscarinic agonist pilocarpine.

177 ring walking or during rhythms evoked by the muscarinic agonist pilocarpine.

178 nce to seizures induced by the non-selective muscarinic agonist pilocarpine.

179 oncentrating hormone, TNRNFLRFamide, and the muscarinic agonist pilocarpine] in stomatogastric gangli

180 The non-selective muscarinic agonists pilocarpine, oxotremorine, RS-86, S-

181 phrenia, and there is clinical evidence that muscarinic agonists possess both antipsychotic and proco

182 Optimal m1 muscarinic agonist potency was achieved when the 1,2,5-t

183 ed excitatory postsynaptic currents, whereas muscarinic agonists potently increased inhibitory postsy

184 Muscarinic agonists produced a concentration-dependent e

185 Pilocarpine (PILO), a muscarinic agonist, produces status epilepticus when adm

186 Muscarinic agonists promote recovery from dauer arrest i

187 Muscarinic agonists promoted microtubule depolymerizatio

188 muscarinic M1 receptors, bath application of muscarinic agonist reduced the maximal Po of Kv7.2/7.3 c

189 ntricular administration of centrally active muscarinic agonists resulted in robust analgesic effects

190 In phosphatidylinositol hydrolysis assays, muscarinic agonists showed greater potency at the HM(1)(

191 NHE1 is critical for regulating pHi during a muscarinic agonist-stimulated acid challenge and probabl

192 the rate of intracellular pH recovery from a muscarinic agonist-stimulated acid load was significantl

193 ator of intracellular pH in both resting and muscarinic agonist-stimulated acinar cells and suggest t

194 The spontaneous and muscarinic agonist-stimulated in vivo phasic contraction

195 y of ubiquitination of endogenous InsP3Rs in muscarinic agonist-stimulated SH-SY5Y human neuroblastom

196 By contrast, muscarinic agonist stimulation of the c-Jun NH2-terminal

197 and is principally under neural control with muscarinic agonists, substance P, and vasoactive intesti

198 In arteries, muscarinic agonists such as acetylcholine release an uni

199 6beta-Acyloxy(nor)tropanes and classical muscarinic agonists, such as muscarine and oxotremorine,

200 rebral hyperemic response to oxotremorine, a muscarinic agonist that increases cerebral blood flow (C

201 In the presence of a muscarinic agonist, the AHP of a subset of these interne

202 e volume of saliva secreted in response to a muscarinic agonist, the primary in situ salivation signa

203 and that there is no requirement for potent muscarinic agonists to mimic acetylcholine interactions

204 fication, that although all areas respond to muscarinic agonists to some extent, only some areas are

205 Regulation of APP processing by the muscarinic agonist treatment occurred not only in normal

206 Muscarinic agonist treatment of hOPCs resulted in a spec

207 ulfide cross-linking patterns indicated that muscarinic agonists trigger a separation of the N-termin

208 and compared it to a number of direct acting muscarinic agonists, two cholinesterase inhibitors and a

209 t the actions on KCNQ channels by Src and by muscarinic agonists use distinct mechanisms.

210 The M current is modulated by muscarinic agonists via G-proteins and an unidentified d

211 ound that, although the release of Ca2+ by a muscarinic agonist was reduced by high concentrations of

212 rd currents activated by 8-bromc-cGMP and by muscarinic agonist were compared in N1E-115 mouse neurob

213 In contrast, inverse muscarinic agonists were found to increase the proximity

214 Muscarinic agonists were tested in two models indicative

215 Muscarinic agonists, which produce an inward current in

216 ta-Acetoxynortropane (5) represents a potent muscarinic agonist with apparent selectivity toward M2-r

217 Other interneurons responded to muscarinic agonists with a hyperpolarization or a biphas

218 lso compared the RA(i) estimates of selected muscarinic agonists with a relative estimate of the prod

219 understand the nature of the interaction of muscarinic agonists with the m1 receptor using a nine am

220 idences of the antipsychotic activity of the muscarinic agonist xanomeline prompted us to investigate